Sodium dichloroacetate
Based on 30 publication(s) in Google Scholar
Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na+-K+-2Cl− cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS). Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers.
For research use only. We do not sell to patients.
- Purity: 99.78%
- CAS No.: 2156-56-1
- Formula: C2HCl2NaO2
- Molecular Weight:150.92
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sodium dichloroacetate
More- Signal Transduct Target Ther. 2022 Sep 1;7(1):303. [Abstract]
- Redox Biol. 2025 Apr:81:103553. [Abstract]
- Adv Sci (Weinh). 2025 Jul 29:e05436. [Abstract]
- Adv Sci (Weinh). 2025 May;12(20):e2413709. [Abstract]
- Cell Death Differ. 2025 Mar;32(3):530-545. [Abstract]
- Cell Death Dis. 2023 Nov 7;14(11):722. [Abstract]
- Cell Death Dis. 2021 Sep 6;12(9):837. [Abstract]
- Clin Cancer Res. 2026 Apr 17. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Mar 11;122(10):e2404899122. [Abstract]
- Cancer Drug Resist. 2020 Sep 4;3(4):947-958. [Abstract]
- Fundam Res. 2023 Mar 6;4(4):820-828. [Abstract]
- J Autoimmun. 2025 May:153:103411. [Abstract]
- J Ethnopharmacol. 2024 Aug 10:330:118235. [Abstract]
- Cell Mol Life Sci. 2025 Oct 28;82(1):370. [Abstract]
- Biochem Pharmacol. 2024 Jul:225:116294. [Abstract]
- Life Sci. 2023 Jan 1:312:121192. [Abstract]
- Inflammation. 2026 Jan 16;49(1):49. [Abstract]
- Cancers (Basel). 2022 Oct 10;14(19):4966. [Abstract]
- Cell Signal. 2026 Jun 27:112701. [Abstract]
- Cell Signal. 2023 Sep:109:110747. [Abstract]
- J Trace Elem Med Biol. 2023 Jul:78:127147. [Abstract]
- J Biol Chem. 2022 Mar 4:101775. [Abstract]
- J Proteome Res. 2025 Nov 7. [Abstract]
- Exp Cell Res. 2021 Sep 1;406(1):112755. [Abstract]
- Mol Reprod Dev. 2021 Jun;88(6):405-415. [Abstract]
- bioRxiv. 2026 Jun 12:2026.06.11.731694. [Abstract]
- bioRxiv. 2026 May 21.
- Jacobs J Environ Sci. 2025 Sep 12.
- Oxid Med Cell Longev. 2021 Jun 4:2021:6633419. [Abstract]
- Oxid Med Cell Longev. 2021 Jun 27;2021:5549047. [Abstract]
Customer Validation & Images
-
IF
-
WB
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
PDHK; Reactive oxygen species (ROS); Apoptosis; NKCC[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
>100 μM
Compound: Na-DCA
|
Anticancer activity against mouse 4T1 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
Anticancer activity against mouse 4T1 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31509699] |
| A-375 | IC50 |
>100 μM
Compound: Na-DCA
|
Anticancer activity against human A375 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
Anticancer activity against human A375 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31509699] |
| A-375 | IC50 |
20.1 mM
Compound: DCA
|
Antiproliferative activity against human A375 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human A375 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33550182] |
| A549 | IC50 |
1011 μM
Compound: DCA
|
Anticancer activity against human A549 cells after 72 hrs by MTT assay
Anticancer activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 20663593] |
| A549 | IC50 |
19.5 mM
Compound: DCA
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33550182] |
| A549 | IC50 |
20.1 mM
Compound: DCA
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30470491] |
| A549 | IC50 |
23.58 mM
Compound: DCA
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 27006991] |
| A549 | IC50 |
4286 μM
Compound: DCA
|
Cytotoxicity against human A549 cells after 68 hrs by MTT assay
Cytotoxicity against human A549 cells after 68 hrs by MTT assay
|
[PMID: 23067553] |
| Bel-7402 | IC50 |
860 μM
Compound: DCA
|
Anticancer activity against human Bel7402 cells after 72 hrs by MTT assay
Anticancer activity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 20663593] |
| BGC-823 | IC50 |
1051 μM
Compound: DCA
|
Anticancer activity against human BGC823 cells after 72 hrs by MTT assay
Anticancer activity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 20663593] |
| CCD-841CoN | IC50 |
12.5 μM
Compound: SDA
|
Cytotoxicity against human CRL1790 cells assessed as inhibition of cell growth
Cytotoxicity against human CRL1790 cells assessed as inhibition of cell growth
|
[PMID: 31864797] |
| HCT-116 | IC50 |
>100 μM
Compound: Na-DCA
|
Anticancer activity against human HCT116 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
Anticancer activity against human HCT116 cells expressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31509699] |
| HCT-116 | IC50 |
14.8 μM
Compound: SDA
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth
Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth
|
[PMID: 31864797] |
| HCT-116 | IC50 |
9.8 mM
Compound: DCA
|
Antiproliferative activity against human HCT-116 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33550182] |
| KB | IC50 |
1424 μM
Compound: DCA
|
Anticancer activity against human KB cells after 72 hrs by MTT assay
Anticancer activity against human KB cells after 72 hrs by MTT assay
|
[PMID: 20663593] |
| KB 3-1 | IC50 |
5883 μM
Compound: DCA
|
Cytotoxicity against human KB-3-1 cells after 68 hrs by MTT assay
Cytotoxicity against human KB-3-1 cells after 68 hrs by MTT assay
|
[PMID: 23067553] |
| L02 | IC50 |
>100 μM
Compound: Na-DCA
|
Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31509699] |
| L02 | IC50 |
21.7 mM
Compound: DCA
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 33550182] |
| MCF7 | IC50 |
>100 μM
Compound: Na-DCA
|
Anticancer activity against human MCF7 cells overexpressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
Anticancer activity against human MCF7 cells overexpressing PDK assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31509699] |
| MCF7 | IC50 |
12.35 mM
Compound: DCA
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 27006991] |
| MCF7 | IC50 |
13.4 mM
Compound: DCA
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33550182] |
| NCI-H1650 | IC50 |
16.3 mM
Compound: DCA
|
Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30470491] |
| NCI-H460 | IC50 |
3892 μM
Compound: DCA
|
Cytotoxicity against human H460 cells after 68 hrs by MTT assay
Cytotoxicity against human H460 cells after 68 hrs by MTT assay
|
[PMID: 23067553] |
| PC-3 | IC50 |
15.7 mM
Compound: DCA
|
Antiproliferative activity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33550182] |
| SH-SY5Y | IC50 |
17.4 mM
Compound: DCA
|
Antiproliferative activity against human SHSY-5Y cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human SHSY-5Y cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33550182] |
Sodium dichloroacetate increases ROS generation in mitochondria. Sodium dichloroacetate affects cell growth and viability through the ROS production increase derived from the promotion of oxidative metabolism. The effects of Sodium dichloroacetate on multiple myeloma cell viability, cell cycle arrest, and apoptotic cell death were associated with pyruvate dehydrogenase kinases (PDK) inhibition, restored pyruvate dehydrogenase (PDH) activity, and the promotion of oxidative metabolism in association with increased intracellular ROS production which depends on the Sodium dichloroacetate dose. The Sodium dichloroacetate effects cooperated with C I inhibition promoting the oxidative stress in rat VM-M3 glioblastoma cells. Increased ROS levels in Sodium dichloroacetate-treated cancer cells are related to the induction of apoptosis associated with the increased cytochrome c expression. Sodium dichloroacetate causes ROS-dependent T-cell differentiation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
A single Sodium dichloroacetate dose causes a significantly higher 24 h diuresis in Wistar male rats, and the increased diuresis is related to NKCC2 inhibition. The NKCC2 is more abundant in kidneys of intact females compared to intact males, with a greater transporter density in Sprague-Dawley female rats[1].
The oral Sodium dichloroacetate bioavailability in na ve male rats dosed 5, 20 and 100 mg/kg is significantly lower than in GSTζ-depleted ones (10%, 13%, 81% and 31%, 75%, 100%, respectively). The liver extraction of Sodium dichloroacetate in the GSTζ-depleted rats has linear kinetics, but it decreases with the metabolism saturation at higher doses[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2156-56-1
-
Appearance Solid
-
Molecular Weight 150.92
-
Formula C2HCl2NaO2
-
Color White to off-white
-
SMILES
O=C(O[Na])C(Cl)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response. [Abstract]2022 Sep 1;7(1):303. PMID: 36045132 -
Redox Biol
Histone lactylation drives liver cancer metastasis by facilitating NSF1-mediated ferroptosis resistance after microwave ablation. [Abstract]2025 Apr:81:103553. PMID: 39970777 -
Adv Sci (Weinh)
2025 Jul 29:e05436. PMID: 40726407 -
Adv Sci (Weinh)
UGDH Lactylation Aggravates Osteoarthritis by Suppressing Glycosaminoglycan Synthesis and Orchestrating Nucleocytoplasmic Transport to Activate MAPK Signaling. [Abstract]2025 May;12(20):e2413709. PMID: 40150862 -
Cell Death Differ
Tufm lactylation regulates neuronal apoptosis by modulating mitophagy in traumatic brain injury. [Abstract]2025 Mar;32(3):530-545. PMID: 39496783 -
Cell Death Dis
Pyruvate dehydrogenase kinase 1 protects against neuronal injury and memory loss in mouse models of diabetes. [Abstract]2023 Nov 7;14(11):722. PMID: 37935660 -
Cell Death Dis
Mitochondrial dysfunction induces radioresistance in colorectal cancer by activating [Ca2+]m-PDP1-PDH-histone acetylation retrograde signaling. [Abstract]2021 Sep 6;12(9):837. PMID: 34489398
Sodium dichloroacetate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Sep 6;12(9):837. [Abstract]
Western blot analysis of PDH, H3K9ac, H3K56ac, and DNA repair proteins in NC cells and ROT cells with or without DCA (5 mM) for 6 h and 24 h in the ROT group.
-
Clin Cancer Res
Lactate-induced lactylation enhances BMAL1 transcription and nuclear translocation, promoting bevacizumab resistance in glioblastoma through VEGFA. [Abstract]2026 Apr 17. PMID: 41995718 -
Proc Natl Acad Sci U S A
2025 Mar 11;122(10):e2404899122. PMID: 40030031 -
Cancer Drug Resist
Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells. [Abstract]2020 Sep 4;3(4):947-958. PMID: 35582217 -
Fundam Res
Astrocytic pyruvate dehydrogenase kinase-lactic acid axis involvement in glia-neuron crosstalk contributes to morphine-induced hyperalgesia in mice. [Abstract]2023 Mar 6;4(4):820-828. PMID: 39161415
Sodium dichloroacetate purchased from MedChemExpress. Usage Cited in: Fundam Res. 2023 Mar 6;4(4):820-828. [Abstract]
The PDK4 inhibitor DCA was diluted with saline to a concentration of 20 mg/ml, and injected intrathecally (i.t., 10 μl) 30 min before morphine. Immunostaining analysis of the activity of GFAP in SDHs was performed.
Sodium dichloroacetate purchased from MedChemExpress. Usage Cited in: Fundam Res. 2023 Mar 6;4(4):820-828. [Abstract]
The PDK4 inhibitor DCA was diluted with saline to a concentration of 20 mg/ml, and injected intrathecally (i.t., 10 μl) 30 min before morphine. Protein levels of PDK4, p-S293-PDH, and p-S300-PDH in SDHs were measured.
Sodium dichloroacetate purchased from MedChemExpress. Usage Cited in: Fundam Res. 2023 Mar 6;4(4):820-828. [Abstract]
The PDK4 inhibitor DCA was diluted with saline to a concentration of 20 mg/ml and injected intrathecally (i.t., 10 μl) 30 min before morphine. The accumulation of lactate in SDHs was detected with the lactate assay; n = 4
-
J Autoimmun
Neutrophil extracellular traps induce trophoblasts pyroptosis via enhancing NLRP3 lactylation in SLE pregnancies. [Abstract]2025 May:153:103411. PMID: 40179478 -
J Ethnopharmacol
Exploration of the underlying mechanism of Astragaloside III in attenuating immunosuppression via network pharmacology and vitro/vivo pharmacological validation. [Abstract]2024 Aug 10:330:118235. PMID: 38648891 -
Cell Mol Life Sci
The transcription factor RBPJ is required for inflammatory macrophage activation in thoracic aortic dissection by mediating mechanotransduction-induced glycolysis. [Abstract]2025 Oct 28;82(1):370. PMID: 41148245 -
Biochem Pharmacol
Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma. [Abstract]2024 Jul:225:116294. PMID: 38754557 -
Life Sci
SIRT6 inhibits hypoxia-induced pulmonary arterial smooth muscle cells proliferation via HIF-1α/PDK4 signaling. [Abstract]2023 Jan 1:312:121192. PMID: 36396113
Sodium dichloroacetate purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Jan 1:312:121192. [Abstract]
Sodium dichloroacetate (DCA; 10 mM; 48 h) significantly inhibits hypoxia-induced proliferation of HPASMCs (Fig I) , and markedly increases the apoptosis rate (Fig J).
-
Inflammation
Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation. [Abstract]2026 Jan 16;49(1):49. PMID: 41543766 -
Cancers (Basel)
2022 Oct 10;14(19):4966. PMID: 36230889 -
Cell Signal
PDK4-dependent lactate production and lactylation promote renal calcium oxalate crystal-induced EMT and mitochondrial dysfunction via the TGF-β/SMAD3/GPX4 axis. [Abstract]2026 Jun 27:112701. PMID: 42364861 -
Cell Signal
2023 Sep:109:110747. PMID: 37286120 -
J Trace Elem Med Biol
Sodium selenite inhibits proliferation of lung cancer cells by inhibiting NF-κB nuclear translocation and down-regulating PDK1 expression which is a key enzyme in energy metabolism expression. [Abstract]2023 Jul:78:127147. PMID: 36963369 -
J Biol Chem
Mitochondrial pyruvate carrier blockade results in decreased osteoclastogenesis and bone resorption via regulating mitochondrial energy production. [Abstract]2022 Mar 4:101775. PMID: 35257748 -
J Proteome Res
Regulating Energy Metabolism to Induce the Release of VOC Biomarkers in Lung Cancer Cells. [Abstract]2025 Nov 7. PMID: 41201462 -
Exp Cell Res
Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells. [Abstract]2021 Sep 1;406(1):112755. PMID: 34332981 -
Mol Reprod Dev
Dysfunction in Sertoli cells participates in glucocorticoid-induced impairment of spermatogenesis. [Abstract]2021 Jun;88(6):405-415. PMID: 34032349 -
bioRxiv
Citrate Compartmentalization Controls Calcium-Dependent Cytokine Production in Effector T Cells. [Abstract]2026 Jun 12:2026.06.11.731694. PMID: 42327233 -
-
-
Oxid Med Cell Longev
α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells. [Abstract]2021 Jun 4:2021:6633419. PMID: 34211631 -
Oxid Med Cell Longev
NOX4-Derived ROS Mediates TGF- β 1-Induced Metabolic Reprogramming during Epithelial-Mesenchymal Transition through the PI3K/AKT/HIF-1 α Pathway in Glioblastoma. [Abstract]2021 Jun 27;2021:5549047. PMID: 34257808
Solvent & Solubility
H2O : 100 mg/mL (662.60 mM; Need ultrasonic)
DMSO : 25 mg/mL (165.65 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (662.60 mM); Clear solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Stakišaitis D, et al. The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo. Cancers (Basel). 2019 Aug 20;11(8). pii: E1210. [Content Brief]
[2]. Hossain M, et al. Cytotoxic derivatives of dichloroacetic acid and some metal complexes. Arch Pharm (Weinheim). 2022 Nov;355(11):e2200236. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 6.6260 mL | 33.1301 mL | 66.2603 mL | 165.6507 mL |
| 5 mM | 1.3252 mL | 6.6260 mL | 13.2521 mL | 33.1301 mL | |
| 10 mM | 0.6626 mL | 3.3130 mL | 6.6260 mL | 16.5651 mL | |
| 15 mM | 0.4417 mL | 2.2087 mL | 4.4174 mL | 11.0434 mL | |
| 20 mM | 0.3313 mL | 1.6565 mL | 3.3130 mL | 8.2825 mL | |
| 25 mM | 0.2650 mL | 1.3252 mL | 2.6504 mL | 6.6260 mL | |
| 30 mM | 0.2209 mL | 1.1043 mL | 2.2087 mL | 5.5217 mL | |
| 40 mM | 0.1657 mL | 0.8283 mL | 1.6565 mL | 4.1413 mL | |
| 50 mM | 0.1325 mL | 0.6626 mL | 1.3252 mL | 3.3130 mL | |
| 60 mM | 0.1104 mL | 0.5522 mL | 1.1043 mL | 2.7608 mL | |
| 80 mM | 0.0828 mL | 0.4141 mL | 0.8283 mL | 2.0706 mL | |
| 100 mM | 0.0663 mL | 0.3313 mL | 0.6626 mL | 1.6565 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Sodium dichloroacetate Related Classifications
HY-Y0445A Related Classifications
Powered by Bioz